Body mass index at 11-13 weeks' gestation and pregnancy complications.

Objective: To examine the association between body mass index (BMI) at 11-13 weeks' gestation and a wide range of adverse pregnancy outcomes after adjustment for confounding factors in obstetric history and maternal characteristics.

Methods: This was a prospective screening study for adverse obstetric outcomes in women with singleton pregnancies attending for their first routine hospital visit at 11(+0)-13(+6) weeks of gestation. The maternal weight and height were measured and the BMI was calculated.

Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus.

Background: Visfatin and adiponectin are produced by adipose tissue and have opposite effects on insulin resistance. Circulating concentrations of these biomarkers are altered in type 2 diabetes mellitus. We sought to examine the potential value of maternal serum visfatin and adiponectin concentrations in early pregnancy as potential biomarkers in the prediction of gestational diabetes mellitus (GDM).

Maternal serum adiponectin at 11-13 weeks of gestation in pregnancies delivering small for gestation neonates.

Objective: To investigate whether maternal serum levels of adiponectin in the first trimester are altered in pregnancies that subsequently deliver small for gestational age (SGA) neonates.

Methods: Maternal serum adiponectin and pregnancy-associated plasma protein A (PAPP-A) were measured at 11-13 weeks' gestation in 50 singleton normotensive pregnancies that delivered SGA neonates and 300 non-SGA controls. The median adiponectin and PAPP-A levels in the SGA and non-SGA groups, expressed as multiple of the unaffected median (MoM), were compared.